scispace - formally typeset
M

Mark R. Alderson

Researcher at PATH

Publications -  84
Citations -  7591

Mark R. Alderson is an academic researcher from PATH. The author has contributed to research in topics: Antigen & T cell. The author has an hindex of 45, co-authored 82 publications receiving 7236 citations. Previous affiliations of Mark R. Alderson include Amgen & Infectious Disease Research Institute.

Papers
More filters
Journal ArticleDOI

Fas ligand mediates activation-induced cell death in human T lymphocytes.

TL;DR: In this article, a significant proportion of previously activated human T cells undergo apoptosis when triggered through the CD3/T cell receptor complex, a process termed activation-induced cell death (AICD).
Journal ArticleDOI

Interleukin 1 signaling occurs exclusively via the type I receptor.

TL;DR: It is concluded that a very small number of type I receptors is sufficient to mediate all of the actions of IL-1 which are examined here and that the function of the type II receptor may not be to transduce signals.
Journal ArticleDOI

CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40.

TL;DR: In this article, CD40 ligand-transfected cells provided a potent costimulus for monocyte TNF-alpha and IL-6 production in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-3, or IFN-gamma.
Journal ArticleDOI

Fas transduces activation signals in normal human T lymphocytes.

TL;DR: The data demonstrate that in addition to a role in the induction of apoptosis in certain transformed cell lines, the Fas protein may also play an important role inThe activation and proliferation of normal T cells.